AVBP · Forms 3, 4, 5
Insider trades at ArriVent BioPharma, Inc.
No open-market insider buys or sells at ArriVent BioPharma, Inc. in the last 90 days; 10 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for ArriVent BioPharma, Inc. (AVBP) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for ArriVent BioPharma, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Merdad Parsey | Director | Options or other derivatives | Form 4 | ||||
| Kristine Peterson | Director | Options or other derivatives | Form 4 | ||||
| John Hohneker | Director | Options or other derivatives | Form 4 | ||||
| Chris Nolet | Director | Options or other derivatives | Form 4 | ||||
| Robin LaChapelle | Chief Operating Officer | Options or other derivatives | Form 4 | ||||
| Stuart Lutzker | President of R&D | Options or other derivatives | Form 4 | ||||
| Winston Kung | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Zhengbin Yao | President and CEO | Options or other derivatives | Form 4 | ||||
| James Paul Kastenmayer | General Counsel | Options or other derivatives | Form 4 | ||||
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% owner | Sell | 555,555 | $23.37 | $13M | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.